Clinical Trials Logo
  1. Home
  2. Gastric Adenocarcinoma
  3. NCT03246516
  4. Details
NCT03246516 Clinical Trial

Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers

Gastric Adenocarcinoma Clinical Trial

— DELOGAST  

Official title:
Individual and Socio-economic Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT03246516
Other study ID # 2015_74
Secondary ID 2015-A01986-43
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 1, 2017
Est. completion date May 2025

Study information
Verified date October 2022
Source University Hospital, Lille
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the role of socioeconomic and individual factors in the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) in oeso-gastric cancer.

Description:

Reducing the time between the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) is essential to improve the vital prognosis and quality of life of patients. Recent data suggest that some sociocognitive and emotional determinants may explain patient delay from a complementary point of view. The main objective of this study is to assess whether, in oeso-gastric cancer, patient delay is linked to these sociocognitive and emotional factors, in addition to previously known factors. We intend to include in this study 300 patients with a not yet treated oeso-gastric cancer diagnosed in one of 10 health centres in the North of France region. The collected data will be analysed to underline the differences between patients who consulted a doctor earlier versus those who consulted later with a cut off at 8 weeks.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 258
Est. completion date May 2025
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - age = 18 years - oesophageal, oeso-gastric junction or gastric cancer non treated cancer - patient informed of his diagnosis - speak fluent french Exclusion Criteria: - history of cancer - psychological history - patient under guardianship- - fortuitous diagnosis of cancer

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Questionnaire
Auto and hetero questionnaires: STAI Y B, State-Trait Anxiety Inventoriage Brief COPE RHHI-24, Revised Health Hardiness Inventory IPQ-R, Illness Perception Questionnaire

Locations
Country Name City State
France Centre hospitalier de Béthune Béthune
France Centre Hospitalier de Boulogne sur mer Boulogne-sur-Mer
France Centre hospitalier de Calais Calais
France centre Léonard de Vinci Dechy
France Centre d 'oncologie Dunkerquois Dunkerque
France Centre oscar Lambret Lille
France CHRU, Hôpital Claude Huriez Lille
France Centre hospitalier de Roubaix Roubaix
France Centre Hospitalier de Seclin Seclin
France Centre hospitalier de valenciennes Valenciennes

Sponsors (2)
Lead Sponsor Collaborator
University Hospital, Lille University of Lille Nord de France

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Time limit of first doctor consultation Median time between date of symptoms appearance and date of first consultation baseline
Secondary Time limit of system of care Median time between date of he beginning of clinical investigations and the beginning of treatment baseline
Secondary cTNM Stage Stage TNM by distinguishing the early stages (I, II) vs. (III, IV) baseline
Secondary clinical variables (i.e medical history, symptoms, entry into care pathway) clinical variables associated with time of first doctor consultation baseline
Secondary Socio-cognitive variables Socio-cognitive variables associated with time of first doctor consultation baseline
Secondary Emotional variables Emotional variables associated with time of first doctor consultation baseline
Secondary Survival At 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05977998 - A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology Phase 2
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT03257163 - Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Phase 2
Completed NCT02128243 - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Phase 2
Completed NCT01178944 - Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer Phase 2
Terminated NCT00209079 - Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma Phase 2
Terminated NCT02862535 - Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma Phase 1
Active, not recruiting NCT05008783 - A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma Phase 3
Recruiting NCT04430738 - Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers Phase 1/Phase 2
Recruiting NCT04114136 - Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Phase 2
Completed NCT03196232 - Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer Phase 2
Recruiting NCT04047953 - Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma N/A
Completed NCT02864381 - Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Phase 2
Completed NCT02891447 - Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer Phase 2
Terminated NCT04032704 - A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Phase 2
Terminated NCT04604132 - Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma Phase 1/Phase 2
Completed NCT02830594 - Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT06038578 - A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer Phase 2
Terminated NCT04099277 - A Study of LY3435151 in Participants With Solid Tumors Phase 1